April 2017

A record amount of money is spent developing new drugs, but drug approval rates are declining and many fatal diseases are left untreated. A big reason behind this is often times current drug testing methods including animal testing don’t accurately predict the human response to drugs. What if we can 3D print living human tissue to test new drugs and study disease?

Tamer Mohamed talks about how 3D printing human tissue will allow us to develop better, safer, and cheaper drugs while reducing our reliance on animal testing. Beyond drug development, Tamer imagines a future where replacement organs are 3D printed using a patient’s own cells, avoiding organ wait lists and the risk of rejection.

Tamer Mohamed is a biomedical engineer, innovator, and entrepreneur. He is President and CEO of Aspect Biosystems Ltd., a biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering – www.aspectbiosystems.com. Tamer can be reached at [email protected]